Jun. 28 –  Jerusalem company Atox Bio and Fast-Track Drugs & Biologics, based in Maryland in the US, have announced a new joint R&D program to continue the development of Atox Bio’s novel mechanism-based immunomodulator peptide, AB103, for the treatment of sepsis and septic shock. The collaboration includes advanced pre-clinical studies and a Phase I clinical trial to be performed at the University of Maryland, Baltimore, in the US. The companies will receive a support grant worth $575,000 from the Israel-US Binational Industrial Research and Development Fund (BIRD). Severe sepsis and septic shock cause some 215,000 deaths in the US every year, and are one of the main causes of death in intensive care. Atox Bio is a subsidiary of Yissum Research Development Company. The company’s novel treatment is based on the research of the company founders, Dr. Raymond Kaempfer and Dr, Gila Arad, from the Faculty of Medicine of the Hebrew University.